Back to search

Article

The novel CFAbd-Score.kid<sup>©</sup>reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first results

2024-10-30

Abstract excerpt

<h4>Background</h4> Recently, elexacaftor/tezacaftor/ivacaftor (ETI), the turning point in the course of Cystic fibrosis (CF), was also approved for children with CF (cwCF) aged 6-11years carrying at least one F508del-mutation. Modulating the causative deficiency in the CF transmembrane conductance regulator channel was found to substantially improve the crucially affected respiratory and digestive CF-manifestatio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
68856ffd-51df-56e5-a8a2-5f1d69a46493
DOI
10.1101/2024.10.29.24316355
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The novel CFAbd-Score.kid<sup>©</sup>reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first resultsDOI 10.1101/2024.10.29.24316355
Dynamics of abdominal symptoms during the start of a new therapy with Elexacaftor/Tezacaftor/Ivacaftor using the novel CFAbd-day2day questionnaireSemantic proximity
Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged ≥12 years – The RECOVER studySemantic proximity
Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.Semantic proximity
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.Semantic proximity
Unveiling the Psychosocial Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Cystic Fibrosis PatientsSemantic proximity
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational StudySemantic proximity
Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis in children 6 to 11 years of ageSemantic proximity
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.Semantic proximity
The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with Cystic Fibrosis in a real-world settingSemantic proximity
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.Semantic proximity
Growth trajectories in Pediatric Cystic Fibrosis Population on Elexacaftor-Tezacaftor-Ivacaftor: Real-Life DataSemantic proximity
The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting.Semantic proximity
Select a neighboring publication to make it the new centre.